VVP
RPRX icon

Venture Visionary Partners’s Royalty Pharma RPRX Stock Holding History

Venture Visionary Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$4.2K – 1313
2022
Q2 		$4.2K Buy
+100
New +$4.1K ﹤0.01% 1431

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Venture Visionary Partners's RPRX Position: Q3 2022 in Review

Venture Visionary Partners sold out of Royalty Pharma (RPRX) in Q3 2022, closing a stake of 100 shares — an estimated $4.2K sold.

Venture Visionary Partners first reported a position in RPRX in Q2 2022 and held it in 1 quarter. The position peaked at $4.2K in Q2 2022. 319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

  • Venture Visionary Partners reported no remaining Royalty Pharma position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 100 Royalty Pharma shares in Q3 2022, an estimated $4.2K.
  • Venture Visionary Partners first reported a position in Royalty Pharma in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Royalty Pharma position peaked at $4.2K in Q2 2022.
  • 319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.